Epoetin beta
Top View
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Injections: Drugs EH Policy
- Both Igm and Igg Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice
- Methoxy Polyethylene Glycol- Epoetin Beta) Injection
- MIRCERA® (Methoxy Polyethylene Glycol-Epoetin Beta) Injection, for Intravenous Or Subcutaneous Use
- Specialty Medications - Medical Benefit
- The Impact of Biosimilar Competition in Europe 2017
- Recombinant Erythropoietin Criteria for Use for Hepatitis C Treatment-Related Anemia
- Self-Administered Specialty Drug List
- DARBEPOETIN ALFA, EPOETIN ALFA, and METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Policy Number: PHARMACY 080.29 T2 Effective Date: October 1, 2017
- Medications to Require Medical Prior Authorization, Effective July 1
- Dose-Finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients Article
- Omontys, INN-Peginesatide
- New Therapies Haemopoietic Growth Factors
- Neorecormon, INN-Epoetin Beta
- Mircera (Methoxy Polyethylene Glycol-Epoetin
- MIRCERA (Methoxy Polyethylene Glycol-Epoetin Beta) RATIONALE